Perifosine News and Research

RSS
Perifosine is a substance that is being studied in the treatment of cancer. Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine.
Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR

Keryx KRX-0401 trial data against colorectal cancer, multiple myeloma to be presented at AACR

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Yakult Honsha, AEZS sign agreement to develop, commercialize and license perifosine

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

New presentations on neuroendocrine tumors at ESMO 12th World Congress on Gastrointestinal Cancer

Aeterna Zentaris announces $12.1 million registered direct offering

Aeterna Zentaris announces $12.1 million registered direct offering